论文信息 - Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma. - 字舞流文

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma.

D. Kondziolka | R. Jain | M. Snuderl | T. Shepherd | A. Chi | A. Chachoua | J. Silverman | Christine Cordova

[1] D. Kondziolka,et al. Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases , 2017, Journal of Neuro-Oncology.

[2] Yi-long Wu,et al. Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3] Matthew Grist,et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity , 2016, Clinical Cancer Research.

[4] Y. Okada,et al. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells , 2015, Oncotarget.

[5] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.